# Nuclide record nct06549465 (trial). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/trials/nct06549465/>
  a schema:MedicalTrial ;
  nuclide:kind "trial" ;
  schema:identifier "nct06549465", "NCT06549465" ;
  schema:name "Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC)"@en ;
  schema:description "A phase 2 trial of the actinium-225 antibody rosopatamab tetraxetan (with an indium-111 version for dosimetry) in prostate cancer, run by Convergent Therapeutics, now recruiting."@en ;
  schema:url <https://nuclide.cc/trials/nct06549465/> ;
  schema:dateModified "2026-10-11"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06549465> ;
  nuclide:status "recruiting" ;
  nuclide:tag "pipeline", "ctgov-ingest" ;
  nuclide:phase "2" ;
  nuclide:related <https://nuclide.cc/isotopes/in-111/>, <https://nuclide.cc/isotopes/ac-225/> ;
  nuclide:indications <https://nuclide.cc/indications/prostate/> ;
  nuclide:companies <https://nuclide.cc/companies/convergent-therapeutics/> .